Copyright
©2012 Baishideng.
World J Obstet Gynecol. Aug 10, 2012; 1(2): 3-13
Published online Aug 10, 2012. doi: 10.5317/wjog.v1.i2.3
Published online Aug 10, 2012. doi: 10.5317/wjog.v1.i2.3
Follow up (82% of centres) |
Follow up for 5 yr at 3 and 9 mo, then 3 monthly for 2 yr then 6 monthly for 3 yr |
Follow up for 5 yr, 3 monthly for the first 2 yr then 6 monthly onwards |
Follow up for 5 yr at 6-12 mo, depending on the pathology |
Follow up for 5 yr; 3 monthly for the first year, 4 monthly for the second year, 6 monthly for third year, and then annually for the fourth and fifth years |
Follow up for 5 yr; every 6 months for 2 yr, then once a year for further 3 yr |
Follow up for 3 yr, six monthly |
All stage I patients are discharged. Patients with stages II and III disease are followed up: 3 monthly for 1 yr, 4 monthly for year 2 and 6 monthly for a third year |
Stage IA fully staged are discharged, and all other patients have annual follow up for 10 yr |
Stage IA completely staged are discharged and all other patients are followed up 6 monthly for 2 yr then annually up to 10 yr then every other year up to 20 yr |
Stage IA fully staged are discharged, and all other patients are followed up monthly for 2 yr, then once in the third year and then discharged |
Follow up is patient initiated. However, patients who retain their ovary are followed up by ultrasound every 6 mo |
Follow up for patients who had fertility sparing surgery 6 monthly for life |
Patients with Stage I disease have only one follow up visit. Patients with stage III are followed for several years |
No follow up (18% of centres) |
- Citation: Winser A, Ledermann JA, Osborne R, Gabra H, El-Bahrawy MA. Survey of the management of borderline ovarian tumors in the United Kingdom. World J Obstet Gynecol 2012; 1(2): 3-13
- URL: https://www.wjgnet.com/2218-6220/full/v1/i2/3.htm
- DOI: https://dx.doi.org/10.5317/wjog.v1.i2.3